A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older

Project: Other project

Project Details

StatusActive
Effective start/end date7/12/227/11/27

Funding

  • Merck Sharp & Dohme Corporation: $16,508.81